A Phase 2 trial of a small molecule drug for the treatment of sudden sensorineural hearing loss, or sudden deafness, failed to meet its primary efficacy endpoint, the developer Sensorion SA, announced on 17 January. The drug, SENS-401, was safe and well-tolerated but did not show a significant improvement in pure tone audiometry, a test used to measure hearing sensitivity. In the trial, it was compared with a placebo and administered to patients over a period of four weeks. The trial, AUDIBLE-S, enrolled 115 patients.
